PL3608334T3 - Białka fuzyjne TATK-CDKL5, kompozycje, formulacje i ich zastosowanie - Google Patents

Białka fuzyjne TATK-CDKL5, kompozycje, formulacje i ich zastosowanie

Info

Publication number
PL3608334T3
PL3608334T3 PL19179287T PL19179287T PL3608334T3 PL 3608334 T3 PL3608334 T3 PL 3608334T3 PL 19179287 T PL19179287 T PL 19179287T PL 19179287 T PL19179287 T PL 19179287T PL 3608334 T3 PL3608334 T3 PL 3608334T3
Authority
PL
Poland
Prior art keywords
tatk
formulations
compositions
fusion proteins
cdkl5 fusion
Prior art date
Application number
PL19179287T
Other languages
English (en)
Polish (pl)
Inventor
Elisabetta CIANI
Franco Laccone
Original Assignee
Alma Mater Studiorum -Universita' Di Bologna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alma Mater Studiorum -Universita' Di Bologna filed Critical Alma Mater Studiorum -Universita' Di Bologna
Publication of PL3608334T3 publication Critical patent/PL3608334T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4737—C-reactive protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/405—Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11022—Cyclin-dependent kinase (2.7.11.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
PL19179287T 2014-02-28 2015-02-27 Białka fuzyjne TATK-CDKL5, kompozycje, formulacje i ich zastosowanie PL3608334T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461946280P 2014-02-28 2014-02-28
EP15736034.8A EP3110837B1 (en) 2014-02-28 2015-02-27 Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
EP19179287.8A EP3608334B1 (en) 2014-02-28 2015-02-27 Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
PCT/IB2015/000999 WO2015128746A2 (en) 2014-02-28 2015-02-27 Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof

Publications (1)

Publication Number Publication Date
PL3608334T3 true PL3608334T3 (pl) 2021-11-22

Family

ID=53539745

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19179287T PL3608334T3 (pl) 2014-02-28 2015-02-27 Białka fuzyjne TATK-CDKL5, kompozycje, formulacje i ich zastosowanie
PL15736034T PL3110837T3 (pl) 2014-02-28 2015-02-27 Białka fuzyjne TATK-CDKL5, kompozycje, formulacje i ich zastosowanie

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15736034T PL3110837T3 (pl) 2014-02-28 2015-02-27 Białka fuzyjne TATK-CDKL5, kompozycje, formulacje i ich zastosowanie

Country Status (33)

Country Link
US (4) US9290746B2 (https=)
EP (2) EP3110837B1 (https=)
JP (2) JP6629747B2 (https=)
KR (1) KR102307276B1 (https=)
CN (1) CN106255706A (https=)
AU (2) AU2015221860B2 (https=)
BR (1) BR112016019868B1 (https=)
CA (1) CA2940401C (https=)
CL (1) CL2016002142A1 (https=)
CR (1) CR20160392A (https=)
CY (2) CY1122644T1 (https=)
DK (2) DK3608334T3 (https=)
DO (1) DOP2016000220A (https=)
EA (2) EA038000B1 (https=)
ES (2) ES2745335T3 (https=)
HR (2) HRP20191511T1 (https=)
HU (2) HUE055282T2 (https=)
IL (2) IL247481B (https=)
LT (2) LT3608334T (https=)
MX (2) MX2016011167A (https=)
MY (1) MY181566A (https=)
NI (1) NI201600127A (https=)
PE (1) PE20161406A1 (https=)
PH (1) PH12016501689A1 (https=)
PL (2) PL3608334T3 (https=)
PT (2) PT3110837T (https=)
RS (2) RS59344B1 (https=)
SG (2) SG10202000537RA (https=)
SI (2) SI3110837T1 (https=)
SM (2) SMT202100478T1 (https=)
SV (1) SV2016005264A (https=)
WO (1) WO2015128746A2 (https=)
ZA (2) ZA201606655B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106255706A (zh) * 2014-02-28 2016-12-21 万校之母-博洛尼亚大学 TATk‑CDKL5融合蛋白、其组合物、配制品以及用途
US20210268072A1 (en) * 2016-06-28 2021-09-02 Alma Mater Studiorum - Universitá Di Bologna TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof
JP2021505135A (ja) * 2017-11-30 2021-02-18 アミカス セラピューティックス インコーポレイテッド Ｃｄｋｌ５発現変異体及びｃｄｋｌ５融合タンパク質
CA3150224A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
CA3156506A1 (en) * 2019-10-30 2021-05-06 Amicus Therapeutics, Inc. Recombinant cdkl5 proteins, gene therapy and production methods
IT202000025423A1 (it) * 2020-10-27 2022-04-27 Ulisse Biomed S P A Uso di proteine per il trattamento di patologie associate a tossine formanti pori o a proteine virali
KR20230128001A (ko) 2020-12-01 2023-09-01 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 엔젤만 증후군의 치료를 위한 조성물 및 이의 용도
EP4387641A4 (en) * 2021-08-18 2025-07-09 Ultragenyx Pharmaceutical Inc RECOMBINANT AAV FORMULATIONS
WO2025050032A1 (en) * 2023-08-31 2025-03-06 Ultragenyx Pharmaceutical Inc. Methods of producing cdkl5 proteins and uses of the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011322715A1 (en) * 2010-10-25 2013-05-23 Centre National De La Recherche Scientifique Treatment of MeCP2-associated disorders
CN106255706A (zh) * 2014-02-28 2016-12-21 万校之母-博洛尼亚大学 TATk‑CDKL5融合蛋白、其组合物、配制品以及用途

Also Published As

Publication number Publication date
KR102307276B1 (ko) 2021-09-30
CN106255706A (zh) 2016-12-21
NZ723371A (en) 2023-11-24
HUE045393T2 (hu) 2019-12-30
CA2940401A1 (en) 2015-09-03
US9944910B2 (en) 2018-04-17
SMT201900504T1 (it) 2019-11-13
ES2885245T3 (es) 2021-12-13
EA202190727A3 (ru) 2021-11-30
KR20170002372A (ko) 2017-01-06
IL247481A0 (en) 2016-11-30
EP3608334B1 (en) 2021-05-19
HRP20211324T1 (hr) 2021-11-26
US9290746B2 (en) 2016-03-22
US20180327725A1 (en) 2018-11-15
PH12016501689B1 (en) 2016-10-03
EA202190727A2 (ru) 2021-07-30
JP2020062022A (ja) 2020-04-23
AU2015221860A1 (en) 2016-09-08
DK3608334T3 (da) 2021-08-23
PT3110837T (pt) 2019-09-12
NI201600127A (es) 2017-03-13
BR112016019868B1 (pt) 2023-11-28
PH12016501689A1 (en) 2016-10-03
PL3110837T3 (pl) 2020-04-30
MX2020001223A (es) 2022-05-31
LT3608334T (lt) 2021-11-25
MY181566A (en) 2020-12-29
SV2016005264A (es) 2017-02-15
JP6629747B2 (ja) 2020-01-15
US10907138B2 (en) 2021-02-02
MX392778B (es) 2025-03-24
IL275435B (en) 2021-07-29
IL275435A (en) 2020-08-31
SG10202000537RA (en) 2020-03-30
CR20160392A (es) 2017-06-12
AU2015221860B2 (en) 2019-09-12
US20200199549A1 (en) 2020-06-25
CY1124727T1 (el) 2022-07-22
HUE055282T2 (hu) 2021-11-29
JP6896050B2 (ja) 2021-06-30
SI3110837T1 (sl) 2019-12-31
EA201691691A1 (ru) 2017-05-31
ZA201906304B (en) 2022-03-30
RS59344B1 (sr) 2019-10-31
AU2019219743B2 (en) 2020-10-29
ES2745335T3 (es) 2020-02-28
EP3110837B1 (en) 2019-06-12
JP2017507655A (ja) 2017-03-23
CL2016002142A1 (es) 2017-09-08
SG11201606863YA (en) 2016-09-29
SI3608334T1 (sl) 2021-11-30
RS62244B1 (sr) 2021-09-30
LT3110837T (lt) 2019-10-10
EP3608334A1 (en) 2020-02-12
US20150247134A1 (en) 2015-09-03
DOP2016000220A (es) 2016-12-15
CA2940401C (en) 2022-11-29
US20160194617A1 (en) 2016-07-07
DK3110837T3 (da) 2019-09-16
BR112016019868A2 (pt) 2017-10-17
SMT202100478T1 (it) 2021-09-14
WO2015128746A2 (en) 2015-09-03
US10584318B2 (en) 2020-03-10
PT3608334T (pt) 2021-08-25
ZA201606655B (en) 2020-05-27
PE20161406A1 (es) 2017-01-14
AU2019219743A1 (en) 2019-09-19
IL247481B (en) 2020-07-30
MX2016011167A (es) 2017-04-06
EA038000B1 (ru) 2021-06-22
HRP20191511T1 (hr) 2019-11-29
WO2015128746A3 (en) 2015-11-26
CY1122644T1 (el) 2021-03-12
EP3110837A2 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
IL276695B (en) Antibodies, pharmaceutical preparations and their uses
IL257030A (en) Multivalent and multispecific cleavage proteins that bind to gitr Preparations containing them and uses thereof
ZA201707749B (en) Compounds targeting proteins, compositions, methods, and uses thereof
IL275435B (en) tatk-cdkl5 fusion proteins, preparations, formulations, and their uses
IL290114A (en) Pharmaceutical preparations, their preparation and uses
EP3191114A4 (en) Occidiofungin formulations and uses thereof
IL263842A (en) Tatk -cdkl5 fusion proteins, compositions, formulations, and use thereof
PT3223796T (pt) Composições farmacêuticas, preparação e suas utilizações
IL252397A0 (en) Pharmaceutical preparations, their preparation and uses
PL3229843T3 (pl) Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
HK1234652A1 (en) Protein formulations